State of New Jersey Common Pension Fund D Has $18.72 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)

State of New Jersey Common Pension Fund D lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 1.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 188,266 shares of the company’s stock after buying an additional 3,143 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Moderna were worth $18,723,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Abbrea Capital LLC raised its holdings in shares of Moderna by 55.8% in the 4th quarter. Abbrea Capital LLC now owns 3,560 shares of the company’s stock valued at $354,000 after purchasing an additional 1,275 shares during the period. Sycomore Asset Management acquired a new stake in Moderna during the 4th quarter valued at $4,667,000. Tokio Marine Asset Management Co. Ltd. lifted its holdings in Moderna by 21.8% during the 4th quarter. Tokio Marine Asset Management Co. Ltd. now owns 10,005 shares of the company’s stock valued at $995,000 after purchasing an additional 1,792 shares during the last quarter. Harvest Fund Management Co. Ltd boosted its position in Moderna by 11.7% during the fourth quarter. Harvest Fund Management Co. Ltd now owns 3,387 shares of the company’s stock worth $333,000 after purchasing an additional 356 shares during the period. Finally, South Dakota Investment Council raised its position in shares of Moderna by 26.8% in the fourth quarter. South Dakota Investment Council now owns 211,563 shares of the company’s stock valued at $21,040,000 after purchasing an additional 44,779 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

MRNA has been the topic of a number of research reports. Canaccord Genuity Group upped their price target on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research note on Friday, February 23rd. HSBC reiterated a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research report on Tuesday, January 2nd. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $125.00 price objective on shares of Moderna in a research note on Thursday, March 28th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $126.49.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the completion of the transaction, the director now owns 2,056,931 shares in the company, valued at $212,645,526.78. The transaction was disclosed in a document filed with the SEC, which is available through this link. In other news, CFO James M. Mock sold 647 shares of Moderna stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction on Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total value of $1,550,700.00. Following the completion of the transaction, the director now owns 2,056,931 shares of the company’s stock, valued at $212,645,526.78. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,954 shares of company stock worth $11,533,976. 15.20% of the stock is owned by company insiders.

Moderna Stock Down 2.5 %

Shares of NASDAQ MRNA traded down $2.67 during trading on Thursday, hitting $106.18. 2,795,353 shares of the company traded hands, compared to its average volume of 4,100,601. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The business’s fifty day moving average is $101.85 and its 200 day moving average is $93.64. The firm has a market capitalization of $40.65 billion, a price-to-earnings ratio of -8.56 and a beta of 1.62. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $142.79.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, beating the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm’s revenue for the quarter was down 44.9% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.61 earnings per share. Equities research analysts predict that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.